Brief: Xeris Biopharma Announces Results Of The Extended Evaluation Of Recorlev From Phase 3 Sonics Study

Xeris Biopharma Holdings

01/11/2022 11:18

Nov 1 (Reuters) - Xeris Biopharma Holdings Inc  XERS.O :
    * XERIS BIOPHARMA ANNOUNCES RESULTS OF THE EXTENDED
EVALUATION OF
RECORLEV® (LEVOKETOCONAZOLE) FROM THE PHASE 3 SONICS STUDY
PUBLISHED IN THE EUROPEAN JOURNAL OF ENDOCRINOLOGY
    * XERIS BIOPHARMA - WITH MEDIAN TREATMENT DURATION OF 15
MONTHS,
LEVOKETOCONAZOLE WAS WELL TOLERATED & NO NEW DRUG-RELATED SAFETY
SIGNALS WERE OBSERVED
    * XERIS BIOPHARMA - RESULTS FURTHER SUPPORTS A ROLE FOR
LEVOKETOCONAZOLE IN LONG-TERM THERAPY FOR PATIENTS WITH
ENDOGENOUS CUSHING'S SYNDROME

Source text for Eikon:  ID:nBwb31tL2a 
Further company coverage:  XERS.O 
 ((Reuters.Briefs@thomsonreuters.com;))